
|Articles|February 1, 2005
Topical AK, non-melanoma cancer options show promise
Newport Beach, Calif. — When it comes to potential topical treatments for actinic keratoses (AKs) and non-melanoma skin cancers, T4N5 liposome lotion (Dimericine, Applied Genetics Inc. Dermatics) leads the pack. The product is composed of the protein T4 endonuclease V in a liposome vehicle.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
The “6-7” Advances for Dermatologists to Look Forward to in 2026
2
Quoin Targets World’s First Approval for Netherton Syndrome Therapy in Saudi Arabia
3
Obagi Launches ALOHA Program to Capture Real-World Insights in Aesthetic Injectables
4
Exploring Type 2 Inflammation and Psoriasis Management at Horizons in Advanced Practice
5



















